Polysaccharides (e.g., Cellulose, Etc.) Patents (Class 424/488)
-
Patent number: 10709787Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.Type: GrantFiled: May 6, 2015Date of Patent: July 14, 2020Assignee: NEMYSIS LIMITEDInventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona
-
Patent number: 10702516Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.Type: GrantFiled: April 16, 2018Date of Patent: July 7, 2020Assignee: Altria Client Services LLCInventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
-
Patent number: 10596192Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using zinc or a zinc chelator to treat rotator cuff conditions are provided.Type: GrantFiled: July 15, 2016Date of Patent: March 24, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Scott M. Riester, John W. Sperling, Andre J. van Wijnen
-
Patent number: 10561607Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described.Type: GrantFiled: December 30, 2016Date of Patent: February 18, 2020Assignee: Harrow IP, LLCInventor: John Scott Karolchyk
-
Patent number: 10426725Abstract: Rapidly dissolving self-supporting films for food or pharmaceutical use comprising: a) a filmogenic substance consisting of a maltodextrin; b) a plasticizer; c) an active principle for food or pharmaceutical use, characterized in that said films are free of hydrocolloids.Type: GrantFiled: July 25, 2016Date of Patent: October 1, 2019Assignee: PHARMAFILM S.R.L.Inventors: Francesco Cilurzo, Paola Minghetti, Luisa Montanari
-
Patent number: 10391139Abstract: Blood Pressure Reduction with Dietary Supplements Abstract A daily dose of 6,000 mg of taurine, 1,000 mg of vitamin C, 150 mg of grape seed extract, 100 mg of vitamin B6, 2 mg of biotin, 2,000 IU of vitamin D3, and 87 mg of magnesium is shown to reduce blood pressure in hypertensive individuals by more than 10 mm Hg.Type: GrantFiled: April 6, 2017Date of Patent: August 27, 2019Assignee: Biotics Research CorporationInventors: William S. Sparks, Daryl L. De Luca, Denis R. De Luca, Mark Houston
-
Patent number: 10383980Abstract: The invention features a composition comprising a self-healing interpenetrating network hydrogel comprising a first network and a second network. The first network comprises covalent crosslinks and the second network comprises ionic or physical crosslinks. For example, the first network comprises a polyacrylamide polymer and second network comprises an alginate polymer.Type: GrantFiled: June 3, 2016Date of Patent: August 20, 2019Assignees: President and Fellows of Harvard College, Seoul National University Industry FoundationInventors: Jeong-Yun Sun, Xuanhe Zhao, Widusha R. K. Illeperuma, Kyu H. Oh, Joost J. Vlassak, Zhigang Suo, Jianyu Li, David J. Mooney
-
Patent number: 10369118Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.Type: GrantFiled: April 20, 2017Date of Patent: August 6, 2019Assignee: Cole Research & Design, LLCInventor: Jeptha N. Cole
-
Patent number: 10342882Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.Type: GrantFiled: September 14, 2016Date of Patent: July 9, 2019Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Jose Manuel Mejia Oneto, Maksim Royzen
-
Patent number: 10328096Abstract: Composition comprising chitosan for use in the prevention and/or treatment of incontinence and/or impotence in a subject undergoing prostatectomy.Type: GrantFiled: July 5, 2017Date of Patent: June 25, 2019Assignees: UNIVERSITA' DEGLI STUDI DI TORINOInventors: Thomas Freier, Stefano Geuna, Francesco Porpiglia
-
Patent number: 10293079Abstract: This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition.Type: GrantFiled: May 5, 2015Date of Patent: May 21, 2019Assignee: SEALANTIS LTD.Inventors: Ohad Kimhi, Ronit Langzam-Sinai, Havazelet Bianco-Peled, Charles Milgrom, Rina Lev
-
Patent number: 10272156Abstract: A liquid composition which comprises an organic liquid diluent and at least one non-ionic cellulose ether having a viscosity of up to 2.33 mPa·s, measured as a 2 wt.-% solution in water at 20° C., is stable over an extended time period. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one cellulose ether by spray-drying. Alternatively a solid dispersion can be produced by blending and extruding at least one active ingredient, at least one cellulose ether having a viscosity of up to 2.33 mPa·s and optionally one or more adjuvants.Type: GrantFiled: October 13, 2016Date of Patent: April 30, 2019Assignee: DOW GLOBAL TECHNOLOGIES LLCInventors: Meinolf Brackhagen, Nicholas S. Grasman, Mark J. Hall, Steven J. Guillaudeu, Robert L. Schmitt, Matthias Knarr
-
Patent number: 10232087Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.Type: GrantFiled: March 29, 2004Date of Patent: March 19, 2019Assignee: LOCATE THERAPEUTICS LIMITEDInventors: Richard Melville France, Robin Andrew Quirk
-
Patent number: 10220047Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.Type: GrantFiled: September 25, 2015Date of Patent: March 5, 2019Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
-
Patent number: 10208403Abstract: A viscose fiber comprises a fiber body including a regenerated cellulosic material and a plurality of microcapsules dispersed in the regenerated cellulosic material. The regenerated cellulosic material is derived from an organic plant material and the plurality of microcapsules containing a phase change material has a transition temperature in the range of 0° C. to 100° C., the phase change material providing thermal regulation based on at least one of absorption and release of latent heat at the transition temperature.Type: GrantFiled: October 27, 2015Date of Patent: February 19, 2019Assignee: OUTLAST TECHNOLOGIES, LLCInventors: Mark Hartmann, James Brice Worley, Matthew North
-
Patent number: 10201576Abstract: The present invention discloses a herbal formulation comprising therapeutic effective amount of plant extract of Woodfordia Floribunda; therapeutic effective amount of plant extract of Centella Asiatica; and an effective amount of at least one pharmaceutically acceptable excipient.Type: GrantFiled: May 20, 2013Date of Patent: February 12, 2019Assignee: Ultratech India LimitedInventor: Bhatia Rishi
-
Patent number: 10195252Abstract: The present invention provides microparticles that deliver in vivo predictable release profiles of at least one chemokine to create a biomimetic chemokine concentration gradient that induces the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and/or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.Type: GrantFiled: August 1, 2013Date of Patent: February 5, 2019Assignee: University Of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Steven R. Little, Riccardo Gottardi, Mintai Peter Hwang, Daniel DeSantis
-
Patent number: 10179779Abstract: The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms of Polymorph Form I, Polymorph Form II, Polymorph Form III, Polymorph Form IV, Polymorph Form V, and Polymorph Form VI, and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.Type: GrantFiled: November 21, 2013Date of Patent: January 15, 2019Assignee: RaQualia Pharma Inc.Inventors: Toyoharu Numata, Hideyuki Aoyama, Kaori Muraji
-
Patent number: 10172954Abstract: The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.Type: GrantFiled: February 17, 2015Date of Patent: January 8, 2019Assignee: MEDESIS PHARMAInventors: Caroline Bauer, Elsa Compte, Olivier Gremy, Laurent Miccoli, Jaime Francisco Angulo-Mora, Jean-Claude Maurel
-
Patent number: 10154976Abstract: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.Type: GrantFiled: February 14, 2017Date of Patent: December 18, 2018Assignee: Bordoloi Biotech, LLCInventors: Binoy K Bordoloi, Nayan J Sarma, Rodney L. Eisenberg
-
Patent number: 10154881Abstract: Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.Type: GrantFiled: August 9, 2013Date of Patent: December 18, 2018Assignee: Arizona Board of Regents for and on behalf of Arizona State UniversityInventors: Kaushal Rege, Huang-Chiao Huang
-
Patent number: 10155824Abstract: A method of producing a carboxymethyl-group-containing modified hyaluronic acid and/or a salt thereof includes a step of subjecting, in a water-containing solvent having a temperature of 30° C. or less, a dissolved raw material hyaluronic acid and/or a salt thereof to a reaction with a haloacetic acid and/or a salt thereof, the water-containing solvent including water or a liquid mixture of a water-soluble organic solvent and water, a ratio of the water-soluble organic solvent in the liquid mixture being 60 v/v % or less.Type: GrantFiled: October 7, 2014Date of Patent: December 18, 2018Assignee: KEWPIE CORPORATIONInventors: Shunichi Fujikawa, Yukina Abe, Kazunori Asaoka, Takushi Yoshida
-
Patent number: 10130584Abstract: The purpose of the present invention is to provide a new disintegrative particulate composition having an optimal balance between the tablet hardness and disintegrability that are mutually opposing properties, and disintegrating tablets for pharmaceuticals and various kinds of foods comprising said composition. The present invention relates to a disintegrative particulate composition comprising milled lactose and/or granulated lactose as an excipient, and to a disintegrating tablet for pharmaceuticals or foods, comprising the disintegrative particulate composition, especially the tablet having tablet hardness of from 20 to 200 N, and disintegration time in water of from 1 to 60 sec.Type: GrantFiled: October 8, 2015Date of Patent: November 20, 2018Assignee: DAICEL CORPORATIONInventors: Takahiro Hiramura, Kiyoshi Ikura, Tomohito Okabayashi, Yoshihisa Takigawa, Naohiro Hashikawa
-
Patent number: 10130711Abstract: The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.Type: GrantFiled: June 18, 2014Date of Patent: November 20, 2018Assignees: The Regents of the University of California, Alchemical Research Holdings, LLCInventors: Jose Manuel Mejia Oneto, Ziyad F. Al-Rashid
-
Patent number: 10111838Abstract: A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C1-C4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.Type: GrantFiled: November 23, 2015Date of Patent: October 30, 2018Assignee: Evonik Roehm GmbHInventors: Shraddha Joshi, Ashish Guha, Vinay Jain
-
Patent number: 10104888Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.Type: GrantFiled: December 15, 2016Date of Patent: October 23, 2018Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
-
Patent number: 10093674Abstract: Disclosed are nucleopeptide compounds that include a nucleobase, and an amino acid. Certain compounds further comprise a glycoside. The compounds may self-assemble to form supramolecular hydrogels. Also, the compounds may be used as a platform to examine specific biological functions (e.g., binding to DNA and RNA) of a dynamic supramolecular system that is able to interact with both proteins and nucleic acids. Other uses include: methods of growing cells and methods of delivering a substance to a cell.Type: GrantFiled: December 2, 2013Date of Patent: October 9, 2018Assignee: Brandeis UniversityInventor: Bing Xu
-
Patent number: 10086113Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.Type: GrantFiled: March 29, 2004Date of Patent: October 2, 2018Assignee: LOCATE THERAPEUTICS LIMITEDInventors: Richard Melville France, Robin Andrew Quirk
-
Patent number: 10080715Abstract: The invention relates to a process for preparing polysaccharide-based microparticles with improved mechanical properties and hydrolytic stability. The spherical particles are useful as exfoliating agents in cosmetic formulations, in replacement of the newly banned plastic microbeads. The method comprises the preparation of hydrogel particles, drying of the particles, and a solid-state reaction that results in the covalent stabilization of the material. The invention also encompasses microparticles made using the method.Type: GrantFiled: April 18, 2017Date of Patent: September 25, 2018Assignee: Bowling Green State UniversityInventors: Giuseppe Giammanco, Alexis Ostrowski
-
Patent number: 10052313Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.Type: GrantFiled: August 12, 2016Date of Patent: August 21, 2018Assignee: PRESBYOPIA THERAPIES, LLCInventors: Gerald Horn, Lee Nordan
-
Patent number: 9950002Abstract: A nanotheranostic probe and its use to facilitate diagnoses, treatment and targeting of amyloid deposits are disclosed herein.Type: GrantFiled: September 16, 2014Date of Patent: April 24, 2018Assignee: Regents of the University of MinnesotaInventor: Karunya K. Kandimalla
-
Patent number: 9926385Abstract: Provided are a method for producing a water-soluble cellulose ether having a low degree of polymerization and enhanced whiteness, and the like. The method includes the steps of: bringing a pulp powder having a multiplication product of less than 0.004 mm2 which is obtained by multiplying a number-average fiber length by a number-average fiber width, each measured with a Kajaani fiber length analyzer, into contact with an alkali metal hydroxide to obtain an alkali cellulose; reacting the alkali cellulose with an etherifying agent to obtain a crude water-soluble cellulose ether having a high degree of polymerization; purifying the crude water-soluble cellulose ether; drying the purified water-soluble cellulose ether; grinding the dried water-soluble cellulose ether into a water-soluble cellulose ether powder; and depolymerizing the water-soluble cellulose ether powder to obtain the water-soluble cellulose ether having a low degree of polymerization.Type: GrantFiled: July 31, 2014Date of Patent: March 27, 2018Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Akira Kitamura, Mitsuo Narita, Takuya Yokosawa, Yuichi Nishiyama
-
Patent number: 9896572Abstract: The invention provides a coffee pulp treatment process comprising (a) Providing coffee pulp, obtainable from a production process for producing green coffee beans from coffee cherries; (b) extracting from the coffee pulp a pectin comprising extract, wherein extraction is performed under acid conditions or alkaline conditions, to provide the pectin comprising extract; (c) enzymatic treatment of the pectin comprising extract, wherein the enzymatic treatment comprises a treatment with one or more enzymes selected from the group consisting of an esterase and a reductase, to provide a enzymatically treated pectin material; and (d) extraction of polyphenol functionalized coffee pectin extract from the enzymatically treated pectin material.Type: GrantFiled: November 27, 2013Date of Patent: February 20, 2018Assignee: Pectcof B.V.Inventor: Andres Felipe Belalcazar Otalora
-
Patent number: 9855206Abstract: Provided is hyaluronic acid gel suitable for cosmetic and medical field. The hyaluronic acid gel contains hyaluronic acid, polycarboxylic acid or oxycarbonic acid, and polyhydric alcohol. The hyaluronic acid gel is produced by drying moisture of an aqueous solution in which the hyaluronic acid, the polycarboxylic acid, and the polyhydric alcohol are uniformly dissolved to be an intended form.Type: GrantFiled: August 2, 2013Date of Patent: January 2, 2018Assignee: COSMED PHARMACEUTICAL CO., LTD.Inventors: Kunio Yoneto, Junya Hasegawa, Naoko Kondou, Ying-shu Quan, Fumio Kamiyama
-
Patent number: 9782365Abstract: The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases.Type: GrantFiled: March 15, 2012Date of Patent: October 10, 2017Assignee: Sanofi-Aventis Deutschland GmbHInventors: Rolf-Stefan Brickl, Herrad-Odilia Krenkel
-
Patent number: 9775931Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.Type: GrantFiled: April 26, 2016Date of Patent: October 3, 2017Assignee: LifeNet HealthInventors: Michael Francis, Roy Ogle
-
Patent number: 9771668Abstract: A fluid-swellable fiber in particular for the use as a surgical suture, the fiber comprising chitosan, the fiber's swelling ratio being less than 100%, and a fabric comprising the fiber. Moreover, a method of manufacturing from a chitosan-containing solution a fiber comprising chitosan, wherein during manufacture, the solution is brought into contact with a coagulation medium containing at least one organic solvent, a method of removing a fiber from a living organism, wherein the fiber is at least partly dissolved in a solvent applied from the outside, and a kit comprising a chitosan containing fiber and a solvent for at least partly dissolving the fiber.Type: GrantFiled: February 2, 2010Date of Patent: September 26, 2017Assignee: Medovent GmbHInventors: Rivelino Montenegro, Thomas Freier
-
Patent number: 9763464Abstract: The invention is directed to a potassium containing preparation or potassium bolus for the prevention or treatment of potassium deficit and optionally other deficit of minerals in ruminants, a process for the production thereof as well as the use thereof. The present invention makes it possible to provide a potassium containing preparation or potassium bolus with a high content of up to 70 wt.-% of potassium salt, based on the total weight of the potassium containing preparation, by adding only a relatively small amount of calcium chloride (15 to 40 wt.-%) and water (10 to 22 wt.-%) to the potassium salt.Type: GrantFiled: August 21, 2013Date of Patent: September 19, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Leif Hoejvang-Nielsen
-
Patent number: 9757499Abstract: Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed.Type: GrantFiled: December 12, 2014Date of Patent: September 12, 2017Assignee: Rutgers, The State University of New JerseyInventors: Noshir Langrana, Devendra Verma, Michelle Previtera
-
Patent number: 9731018Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin.Type: GrantFiled: September 7, 2012Date of Patent: August 15, 2017Assignee: Ferring B.V.Inventors: Varinder Ahuja, Tejas Gunjikar, Balachendar Gundu
-
Patent number: 9731019Abstract: The object of the present invention is novel release systems comprising specific hyaluronic acid amides combined with therapeutically and/or biologically active proteins with a mainly hydrophobic nature, for sustained, slow release over time which increases the efficacy of the medicament and the patient's compliance.Type: GrantFiled: May 30, 2013Date of Patent: August 15, 2017Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Monica Campisi, Cristian Guarise, Davide Renier
-
Patent number: 9675728Abstract: A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds.Type: GrantFiled: September 17, 2003Date of Patent: June 13, 2017Assignee: KCI USA, Inc.Inventors: Breda Mary Cullen, Derek Walter Silcock
-
Patent number: 9675547Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.Type: GrantFiled: December 20, 2012Date of Patent: June 13, 2017Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Koichi Kitamura, Maho Kondo, Kiyoshi Shimoyama, Toru Kurosawa
-
Patent number: 9668979Abstract: The present invention provides a microcapsule pharmaceutical composition of at least a bisquinoline drug. said microcapsule comprises a drug core of a pharmaceutically effective amount of a bisquinoline drug and a polymeric coating over the core. This microcapsule pharmaceutical composition has desirable pharmaceutical properties, including taste masking effect and a high stability.Type: GrantFiled: March 21, 2014Date of Patent: June 6, 2017Assignee: Adare Pharmaceuticals, Inc.Inventors: Christian Stollberg, Giancarla Bianchi, Flavio Fabiani, Luigi Boltri
-
Patent number: 9637470Abstract: Treatments are described for stress disorders and substance use disorders, for example, substance use disorders associated with use of alcohol, cocaine, amphetamines, and the like.Type: GrantFiled: February 22, 2014Date of Patent: May 2, 2017Inventors: Thomas F. Newton, Colin N. Haile
-
Patent number: 9611312Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: GrantFiled: November 22, 2011Date of Patent: April 4, 2017Assignee: ELASTAGEN PTY. LIMITEDInventor: Jens Sommer-Knudsen
-
Patent number: 9597303Abstract: The present invention relates to the use of a 2,5-dihydroxybenzine derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: GrantFiled: September 24, 2015Date of Patent: March 21, 2017Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 9545423Abstract: The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The chitosan can be partially or fully deacetylated, and the tannin can be a monomeric or an oligomeric proanthocyanidin or a hydrolysable tannin. The chitosan-tannin composite material can be a nanoparticle, a hydrogel film, a bio-foam, or a biogel, or the chitosan-tannin composite material can coat a liposome. The composite materials can be used for drug delivery, for antibacterial and/or antifungal applications, for tissue engineering applications, for wound healing applications, or they can be used as adjuvants for vaccination, including oral vaccinations. The invention also provides methods of preparing the composite materials and their various forms.Type: GrantFiled: December 23, 2013Date of Patent: January 17, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Jess Dreher Reed, Christian Gerald Krueger, Sergio Madrigal-Carballo
-
Patent number: 9539215Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.Type: GrantFiled: January 26, 2015Date of Patent: January 10, 2017Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: George John, Praveen Vemula
-
Patent number: 9512495Abstract: Processes for converting lignocellulose to feedstock and downstream products are disclosed. The processes may include acid treatment of lignocellulose to produce a fermentation feedstock. In various instances, the processes include recovery or recycling of acid, such as recovery of hydrochloric acid from concentrated and/or dilute streams. Downstream products may include acrylic acid-based products such as diapers, paper and paper-based products, ethanol, biofuels such as biodiesel and fuel additives, and detergents.Type: GrantFiled: April 2, 2012Date of Patent: December 6, 2016Assignee: Virdia, Inc.Inventors: Aharon Eyal, Robert P. Jansen